A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Necitumumab (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-099
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Sep 2017 Results (n=64) assessing efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer, presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Nov 2016 According to a Merck media release, data from this trial to be presented orally at the 17th World Conference on Lung Cancer (WCLC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top